Immunotherapy has revolutionized the clinical management of many malignancies but is
infrequently associated with durable objective responses when used as a standalone …

In the era of targeted therapy based on genomic alterations, the treatment strategy for
metastatic colorectal cancer (mCRC) has been changing. Before systemic treatment …

Background Patients with non-small-cell lung cancer (NSCLC) that is resistant to PD-1 and
PD-L1 (PD [L]-1)-targeted therapy have poor outcomes. Studies suggest that radiotherapy …

The tumor immune microenvironment is a determinant of response to cancer
immunotherapy and, in many cases, is prognostic for patient survival independently of the …

Stereotactic ablative radiotherapy (SABR) is a standard-of-care for medically-inoperable-
early-stage non-small cell lung cancer (NSCLC). One third of patients progress and …

The majority of cancer patients receive radiotherapy during the course of treatment,
delivered with curative intent for local tumor control or as part of a multimodality regimen …

Even though the discovery of immune checkpoint inhibitors (ICIs) has revolutionized cancer
treatment, a high proportion of patients do not respond. Moreover, some types of cancers are …

Colorectal cancer (CRC) is the third most diagnosed malignancy and a major leading cause
of cancer-related deaths worldwide. Despite advances in therapeutic regimens, the number …

Colorectal cancer (CRC) is the second most common cause of cancer mortality, with
mismatch repair proficient (pMMR) and/or microsatellite stable (MSS) CRC making up more …

The hypothesis that ablative therapies (such as surgery or radiation) can be used to cure
patients with a limited number of metastases was influential in changing practice. Early …